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Summary
	 	 The	majority	of	children	with	the	epidemic	form	of	acute	post-streptococcal	glomerulonephritis	
(APSGN)	have	an	excellent	prognosis,	which	contrasts	with	the	poor	long-term	outcome	of	sporad-
ic	cases.	Therapy	is	largely	supportive.	Rarely,	the	disease	shows	long-term	complications,	worsening	
to	chronic	kidney	disease	requiring	long-term	interventional	measures.	To	compare	the	effective-
ness	of	different	therapeutic	strategies	for	the	prevention	and	treatment	of	APSGN	in	childhood,	
the	authors	reviewed	randomized	controlled	trials	on	the	prevention	and	treatment	of	APSGN	in	
children.	Nine	studies	fit	the	inclusion	criteria.	Primary	outcomes	were	the	development	of	APSGN,	
the	effectiveness	of	medication	for	controlling	hypertension,	and	the	development	of	chronic	re-
nal	failure	in	patients	with	crescentic	glomerulonephritis.	No	advantages	of	antimicrobials	(cefu-
roxim,	ceftibuten,	and	others)	given	for	5	days	were	found	over	penicillin	V	given	for	10	days	(4	
trials).	Nifedipine	showed	advantages	in	controlled	acute	hypertension	(1	trial).	ACE	inhibitors	
(captopril	and	enalapril)	had	better	control	of	blood	pressure	and	echocardiographic	changes	
than	other	antihypertensive	drugs/diuretics	(2	trials).	The	use	of	combined	immunosuppressants	
for	crescentic	poststreptococcal	glomerulonephritis	showed	no	advantages	over	supportive	ther-
apy	alone	(1	study).	The	studies	were	of	small	number	and	with	limitations	that	seriously	weaken	
the	results.
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Background
Acute	poststreptococcal	glomerulonephritis	(APSGN)	is	a	
condition	that	occurs	after	pharyngitis	or	skin	infections	of	
group	A	streptococci.	Typical	APSGN	usually	presents	with	
acute	nephritic	syndrome	with	variable	severity	and	gener-
ally	resolves	without	complications	within	a	short	period.	
Renal	damage	in	APSGN	is	secondary	to	humoral	immunity	
initiated	by	nephritogenic	streptococcal	antigens.	The	for-
mation	of	antigen-antibody	complexes	and	the	glomerular	
deposits	of	circulating	immune	complexes	lead	to	the	acti-
vation	of	the	classical	and	alternative	complement	pathways.	
In	the	acute	stage	of	APSGN,	serum	levels	of	C3	are	low	and	
C4	levels	are	normal	or	only	slightly	depressed.	However,	
a	C3	nephritic	factor	and	autoantibody	against	C3	conver-
tase,	which	is	detectable	during	the	early	stages	of	APSGN,	
may	induce	a	continuous	activation	of	the	alternative	com-
plement	pathway	[1].
APSGN	is	defined	by	the	following	criteria:	acute	onset	of	
glomerulonephritis	with	hematuria	(with	or	without	protein-
uria),	transient	depression	of	serum	C3,	evidence	of	recent	
streptococcal	infection	by	isolation	of	Streptococcus	pyogenes	
in	culture	in	the	previous	three	months,	and/or	abnormal	
streptococcal	serology.	Kidney	failure,	measured	as	an	ele-
vation	of	serum	creatinine	or	a	reduced	estimated	glomer-
ular	filtration	rate,	hypertension,	edema,	and	macroscop-
ic	hematuria,	is	not	included	in	the	diagnostic	criteria	for	
APSAGN	but	indicates	the	severity	of	renal	involvement	and	
the	effectiveness	of	the	intervention	measures	[2].
The	incidence	of	APSGN	varies	among	populations,	and	
microbiological	 factors	 seem	to	be	 involved	[3,4].	 In	re-
cent	decades,	the	prevalence	of	postinfectious	glomerulo-
nephritis	has	tended	to	decline	in	most	industrialized	coun-
tries,	but	high	rates	persist	in	some	developing	communities	
[5].	Based	on	the	Italian	Biopsy	Registry,	the	incidence	of	
APSGN	has	been	estimated	at	0.3	cases	per	100,000	per-
sons/year.	In	particular,	concerning	children	younger	than	
15	years,	the	incidence	varied	from	2.6%	to	3.7%	of	all	pri-
mary	glomerulopathies	[6].	The	incidence	of	APSGN	has	
dropped	over	the	past	decades.	Between	1999	and	2006	the	
incidence	of	APSGN	was	6.4	and	between	1957	and	1973	
it	was	10.9/100,000	persons/year	with	a	prevalence	of	0.64	
vs.	2.18/100,000	persons/year,	respectively.	Today,	pharyn-
gitis	causes	more	APSGN	than	impetigo	[7].
Despite	the	decrease	in	the	incidence	of	poststreptococcal	
diseases	in	some	populations,	the	problem	remains	impor-
tant	[8,9].	Although	rare,	APSGN	can	lead	to	complications	
such	as	crescentic	glomerulonephritis,	hypertension,	and	var-
ious	degrees	of	renal	failure	[10].	Children	followed	for	15	
to	18	years	after	an	APSGN	episode	showed	an	incidence	of	
7.2%	for	non-nephrotic	proteinuria,	5.4%	for	microhema-
turia,	3.0%	for	hypertension,	and	0.9%	for	azotemia	[11].	
A	delay	in	diagnosis	can	occur	frequently	in	children	with	
no	visible	signs	of	hematuria,	hypertension,	and/or	conges-
tive	heart	failure	[12].
Drugs	currently	 in	use	to	treat	the	clinical	conditions	as-
sociated	with	APSGN	are	antibiotics	and	antihyperten-
sive	drugs/diuretics.	Of	course,	antibiotics	are	prescribed	
mainly	to	treat	any	child	with	streptococcal	infections;	an-
tihypertensive	drugs/diuretics	are	the	choice	for	treating	
hypertension,	edema,	hypertensive	encephalopathy,	and	
congestive	heart	failure	during	acute	phases	of	the	disease.	
Immunosuppressants	were	used	in	the	past.
Normally,	APSGN	is	a	benign	condition	and	renal	changes	
rarely	develop	towards	a	chronic	condition.	The	aim	of	this	
systematic	review	was	to	determine	the	effectiveness	of	dif-
ferent	therapeutic	strategies	for	the	prevention	and	treat-
ment	of	APSGN	in	childhood.
Material and Methods
To	review	the	antimicrobial,	antihypertensive,	diuretic,	and	
immunosuppressant	drugs	in	children	with	APSGN,	we	in-
cluded	randomized	controlled	trials	(RCTs)	and	quasi-RCTs.	
Children	aged	from	birth	to	18	years	with	typical	APSGN	
treated	in	a	hospital	or	as	outpatients	were	included	in	this	
study.	For	this	review,	the	diagnosis	of	typical	APSGN	is	de-
fined	as	acute	onset	of	glomerulonephritis	with	hematuria	
(with	or	without	proteinuria),	depression	of	 serum	com-
plement	(C3),	and	evidence	of	previous	streptococcal	in-
fection	[13].	The	enrolled	childhood	population	showed	
clinical	conditions	characterized	by	typical	signs	of	APSGN	
accompanied	by	hypertension,	nephrotic	syndrome,	and/or	
acute	or	chronic	kidney	failure.	Children	with	infective	acute	
glomerulonephritis	for	whom	an	infection	by	Streptococcus 
pyogenes	had	not	been	previously	demonstrated	in	culture	or	
serologically	and	children	not	treated	with	drugs	or	those	
treated	but	for	whom	therapy	was	not	specified	as	to	“how	
and	when”	were	excluded	from	the	cohort.
Trials	involving	any	administration	of	antibiotics,	classical	
anti-hypertensive	drugs,	diuretics,	and	ACE	inhibitors,	ste-
roidal	and	non-steroidal	 immunosuppressants,	or	a	com-
bination	of	drugs	by	a	medical	professional	in	community,	
hospital,	or	outpatient	settings	were	included.	We	compared	
treatments	of	interest	involving	different	therapy	regimens	
and	cases	of	no	intervention.	Primary	outcomes	were	the	
development	of	APSGN,	the	effectiveness	of	medications	in	
controlling	hypertension,	and	the	development	of	chronic	
renal	failure	in	patients	with	crescentic	glomerulonephri-
tis.	Secondary	outcomes	were	hypertension,	cardiac	chang-
es,	and	proteinuria.
Our	search	had	no	language	restrictions.	Terms	used	to	find	
specific	studies	were	“post	streptococcal”	or	“poststreptococ-
cal”,	“glomerulonephritis”,	“children	(1–18	yrs)”,	“clinical	
trial”,	and	“randomized	controlled	trial”.	Relevant	studies	
were	obtained	from	the	following	sources:	 the	Cochrane	
Central	Register	of	Controlled	Trial	 (CENTRAL),	 the	
Cochrane	Renal	Group’s	Specialized	Register,	MEDLINE	
database	(1966–2009),	EMBASE	database	(1980–2009),	and	
SCOPUS	database	(1966–2009).	We	looked	at	other	resourc-
es	such	as	the	bibliographies	of	nephrology	textbooks,	re-
view	articles,	and	other	relevant	studies.
Data	synthesis	and	analyses	were	done	using	the	Mantel-
Haenszel	test.	A	weighted	pooled	treatment	effect	was	cal-
culated	across	the	studies	using	a	random	effects	model.	We	
expressed	the	results	as	the	risk	ratio	(RR)	and	95%	confi-
dence	intervals	(CI)	for	dichotomous	outcomes.	We	evalu-
ated	the	risks	of	biases	discussing	the	adequacy	of	sequence	
generation,	allocation	concealment,	blinding,	and	presence	
of	incomplete	outcome	data.
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results
Trial selection and characteristics
The	Cochrane	Central	Register	of	Controlled	Trials	con-
tained	eleven	records	[14–24].	Of	 these,	nine	were	en-
rolled	in	our	study	because	they	fit	well	with	the	inclusion	
criteria	[14–22],	while	the	trial	by	Faye	et	al.	was	exclud-
ed	from	the	analysis	because	it	did	not	specifically	refer	to	
poststreptococcal	sequelae	[25]	and	that	by	Lord	was	ex-
cluded	[26]	because	it	referred	to	another	trial	[16].	Eight	
records	were	found	in	the	PUBMED	database.	The	Faye	et	
al.	[25]	and	Lord	[26]	trials	were	excluded	for	the	reasons	
mentioned	above.	In	the	end,	six	trials	in	PUBMED	were	
included	 in	 the	analysis.	Of	 these,	only	one	[22],	which	
had	not	been	previously	cited,	was	included	in	the	list	of	
trials.	Four	records	were	found	in	the	EMBASE	database.	
Of	these,	only	one	[16]	was	included	in	our	analysis,	but	
it	had	already	been	identified.	Furthermore,	eight	records	
were	found	in	the	SCOPUS	database.	The	studies	by	Lord	
[26]	and	Faye	et	al.	[25]	were	excluded.	Finally,	three	previ-
ously	identified	trials	were	included	in	the	analysis	[15–17].	
Study ID Participants (n) Inclusion criteria Experimental intervention Definition of renal outcome Follow-up
Antimicrobials (PV=penicillin V, CA= cefuroxime axetil) for prevention of APSGN
Adam 2000 [14] 2264 Culture-proven 
tonsillo-pharyngitis
A) CA 20 mg/kg/d × 5 d
B) PV 50,000 IU/kg × 10 d
Glomerulonephritis 6–12 m
Adam 2000 [16] 4171 Age 1–18 y, clinical and 
laboratory diagnosis of 
tonsillo-pharyngitis
A)  (Amoxicillin/ clavulanate 37.5 
mg/kg/d or ceftibuten 9 mg/kg/d 
or CA 20 mg/kg/d or loracarbef 
15 mg/kg/d or clarithromycin 
15 mg/kg/d or erythromycin 40 
mg/kg/d) × 5 d
B) Oral PV 50,000 IU/kg/d × 10 d
Glomerulonephritis 12 m
Adam 2001 [15] 2099 Age 1–18 y, culture-proven 
streptococcal 
tonsillo-pharyngitis
A) Ceftibuten 9 mg/kg × 5 d
B) PV 50,000 IU/kg × 10 d
Glomerulonephritis 7–8 w
Scholz 2004 [17] 1952 Age 1–17 y, 
tonsillo-pharyngitis
A) CA 20 mg/kg/d × 5 d
B) PV 50,000 IU/kg × 10 d
Glomerulonephritis 1 y
Treatment of hypertension in APSGN
Ribeiro 1992 [18] 30 Age 3–11 y, clinical and 
laboratory diagnosis
A)  Nifedipine 0.25–0.50 mg/kg 
every 8 h
B) Placebo
Blood pressure 
8 h
Tanphaichitr 
1977 [22]
20 Age 4–14 y A)  Furosemide 1–8.5 mg/kg/d, 
fractioned from 1 to 3 doses per os
B) reserpine 0.07 mg/kg, 2–3 times
1. Blood pressure
2. Diuresis 1–4 d
Morsi 1992 [19] 20 Age 4–10 y, 
hypertension
A)  Captopril 0.2 mg/kg, maintenance 
1.5 mg/kg/d
B)  Reserpine 0.02 mg/kg plus 
furosemide 2 mg/kg/d
Blood pressure
3 d
Jankauskiene 
2005 [20]
51 Age 3–16 y, acute tonsillo-
pharyngitis, impetigo, 
acute nephritic syndrome, 
urine changes of APSGN
A)  Enalapril 5-10 mg (6 weeks)
B)  β-blockers, vasodilators, diuretics 
and central acting agents (given 
if needed)
1. Blood pressure
2.  Echocardiographic 
changes 6–8 w
Treatment of crescentic glomerulonephritis from APSGN
Roy 1981 (21) 10 Age 5–16 y, 
comparable crescentic 
glomerulonephritis at renal 
biopsy
A)  Prednisone (1 mg/kg/d), 
azathioprine (1 mg/kg/d), 
cyclophosphamide (1 mg/kg/d), 
dipyridamole (10 mg/kg/d) for 3 
m, heparin for 2 w, followed by 
warfarin
B) Supportive care
Crescentic 
glomerulonephritis 
at renal biopsy
8–60 m
Table 1. Intervention in acute poststreptococcal glomerulonephritis: studies included in the systematic review.
d – day; h – hour; m – month; w – week; y – year.
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Nine	studies	were	included	in	the	meta-analysis	(Table	1),	
among	which	RCTs,	quasi-RCTs,	and	clinical	trials	involv-
ing	10,617	children	of	whom	10,486	were	subjects	in	anti-
microbial	trials,	121	in	antihypertensive/diuretics	trials,	and	
10	in	immunosuppressant	trials.	Six	trials	were	published	
in	English	[14,16,17,19–22],	one	trial	in	German	[15],	and	
two	in	Spanish	[18,23].
Two	studies	[23,24]	did	not	have	suitable	statistical	data	
to	perform	a	meta-analysis	(Table	2).	These	two	trials	ex-
plored	therapy	for	hypertension	and	oliguria	with	furose-
mide	in	36	children	with	APSGN.	Both	studies	agreed	that	
blood	pressure	and	diuresis	were	better	controlled	by	furo-
semide	than	by	no	treatment	at	all	or	by	conventional	an-
tihypertensive	drugs.
Overall,	the	studies	showed	plausible	bias	that	seriously	weak-
ens	confidence	in	the	results.	In	particular,	eight	trials	of	
the	nine	had	randomly	selected	patients	[14–21].	One	study	
[22]	did	not	clarify	how	the	patients	were	allocated	in	each	
group.	Therefore,	none	reported	adequate	allocation	con-
cealments.	One	study	[16]	partially	clarified	the	method	of	
allocation.	No	trial	reported	an	intention	to	treat	analysis.	
Blinding	of	participants	and	investigators	occurred	in	only	
one	trial	[18].	Loss	at	follow-up	was	reported	in	four	trials,	
ranging	between	0	to	37.3%	[14–16,20].
Antimicrobials
The	effects	of	different	antimicrobials	(such	as	cephalospo-
rin)	administered	for	5	days	vs.	penicillin	V	for	10	days	dur-
ing	streptococcal	infections	as	a	preventive	measure	against	
onset	of	APSGN	were	evaluated	by	four	trials.	Two	RCTs	as-
sessed	cefuroxim	treatment	for	5	days	vs.	penicillin	V	for	10	
days	and	found	no	significant	difference	in	the	risk	of	devel-
oping	APSGN	after	6–7	weeks	of	follow-up	(3864	children,	
RR=2.98,	CI:	0.31–28.64)	[14,17].	However,	the	same	con-
clusion	was	reached	in	trials	with	ceftibuten	treatment	vs.	
penicillin	(one	trial,	1803	children,	RR=1.06,	CI:	0.04–25.88)	
[15]	or	other	different	antimicrobials	(one	trial,	4171	chil-
dren,	RR=6.38,	CI:	0.26–156.45)	administered	for	5	days	vs.	
penicillin	V	for	10	days	[16].
Antihypertensives
The	efficacy	of	antihypertensive	 treatment	 is	available	 in	
one	trial	[18],	which	assessed	the	treatment	of	hypertension	
with	nifedipine	vs.	placebo;	it	showed	good	control	of	blood	
pressure	(after	8	hours,	30	children,	MD=–9.8,	CI:	–11.14	to	
–8.46).	However,	one	trial	[22]	that	assessed	hypertension	
and	edema	during	APSGN	treated	with	furosemide	showed	
better	results	than	with	reserpine	(20	children,	RR=0.06,	CI:	
0.00–0.90).	Moreover,	another	trial	[19]	that	assessed	cap-
topril	therapy	vs.	reserpine-furosemide	therapy	for	hyper-
tension	during	APSGN	showed	significantly	better	control	
of	supine	and	standing	blood	pressure	with	ACE	inhibitors	
(20	children,	MD=–8,	CI:	–15.46	to	–0.54).	Another	trial	[20]	
that	assessed	echocardiographic	changes	in	patients	treated	
with	enalapril	or	with	b-blockers,	vasodilators,	diuretics,	and	
central	acting	agents	(given	if	needed)	to	manage	hyperten-
sion	during	APSGN	showed	better	results	after	6–8	weeks	
of	treatment	with	ACE	inhibitors	(left	ventricular	mass,	32	
children,	MD=–7.33,	CI:	–12.32	to	–2.34).
Immunosuppressants
The	effectiveness	of	immunosuppressant	drugs	was	inves-
tigated	by	only	one	trial	[21],	which	compared	quintuple	
therapy	 including	 immunosuppression	with	prednisone,	
azathioprine,	and	cyclophosphamide	for	biopsy-document-
ed	crescentic	PSGN	and	supportive	treatment	alone;	the	re-
sults	showed	no	clinical	advantages	of	the	former	over	the	
latter	 in	outcome	(10	children,	RR=2.0,	CI:	0.26–15.62).	
Moreover,	one	patient	in	the	treatment	group	died	follow-
ing	a	massive	pulmonary	hemorrhage.
discussion
The	majority	of	children	with	the	epidemic	form	of	PSGN	
have	an	excellent	prognosis,	which	contrasts	with	the	poor	
long-term	outcome	of	 sporadic	cases	[5].	Moreover,	 the	
incidence	and	prevalence	of	APSGN	have	decreased	over	
the	past	few	years	[7],	with	an	increased	risk	of	delayed	di-
agnosis	[12].	The	reduced	incidence	of	APSGN	may	agree	
with	the	widespread	use	of	antibiotics,	an	amelioration	of	
Study ID Participants (n) Inclusion criteria
Experimental 
intervention
Definition of renal 
outcome Follow-up Results
Sólomon-
Santibañez 
1971 [23]
20 Age 4–15 y, 
laboratory confirmed 
post-streptococcal 
infection
A)  Furosemide 20 mg 
every 6 h
B)  PV 4,000,000 IU, 
guanethidine (10 mg 
every 6 h)
1. Blood pressure
2. Diuresis
24 hours Blood pressure 
reduction (DBP 82.4 
vs. 85.5) and diuresis 
more pronounced with 
furosemide 
Powell 
1980 [24]
16 Age 4–12 y A) furosemide (2 mg/kg)
B)  methyldopa or 
reserpine or diazoxide
1. Hypertension
2. Oliguria
3. Edema
Weeks 
(unspecified)
I.  Shorter hypertension 
(mean: 4.7 range: 2–9 
d) vs. controls (mean: 
11.0 range: 7–20 d)
II.  Faster edema-free 
(6.8, range: 4–12 d) 
vs. controls (13.9, 
range: 6–23 d)
Table 2. Intervention in acute poststreptococcal glomerulonephritis: studies excluded from the analysis.
d – day; m – month; y – year.
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behavior,	hygiene,	and	both.	Therapy	is	largely	supportive;	
in	most	cases	the	abnormal	immune	response	observed	is	
self-limiting	[5].	Rarely,	the	disease	shows	long-term	com-
plications	and	worsens	to	chronic	kidney	disease	requiring	
long-term	intervention	measures	[11],	even	after	eradica-
tion	of	the	causative	organism	[5].
The	treatment-based	literature	for	children	with	APSGN	is	
inconclusive	since	very	few	studies,	of	poor	quality,	and	no	
evidence-based	guidelines	are	available	as	to	which	drugs,	
if	any,	can	be	used	(and	how)	to	prevent	and	treat	the	com-
plications	that	arise	during	an	acute	episode	or	any	long-
term	complications.	There	are	few	reports	in	the	literature	
of	prospective	and	retrospective	studies	concerning	APSGN	
with	severe	clinical	patterns	treated	with	immunosuppres-
sants,	mostly	with	steroids	alone	[2,10,27–29],	or	in	combi-
nation	with	cyclophosphamide,	in	more	severe	cases	[10].	
Therefore,	no	structured	trials	are	available	that	demon-
strate	substantial	effectiveness	and	usefulness	of	 treating	
severe	forms	of	disease	with	steroids.	However,	the	litera-
ture	reports	few	structured	trials	concerning	antimicrobi-
als,	antihypertension	drugs/diuretics	and	combined	 im-
munosuppressants.
This	systematic	review	of	RCTs	identified	nine	trials,	four	
of	which	compared	two	types	of	antimicrobial	regimens	to	
prevent	APSGN	in	children	with	laboratory-proven	strep-
tococcal	group	A	 infection.	Meta-analyses	showed	no	ad-
vantages	of	cefuroxime	axetil,	ceftibuten,	or	other	antimi-
crobials	given	for	5	days	over	penicillin	V	given	for	10	days	
[14–17].	These	antibiotic	trials	seem	misleading	since	they	
were	not	powered	to	look	at	APSGN.	However,	the	number	
of	cases	of	APSGN	in	all	of	these	trials	was	extremely	low.
Antihypertensive	 treatment	with	nifedipine	given	during	
APSGN	clearly	showed	better	control	of	blood	pressure	than	
placebo	[18].	However,	furosemide	showed	better	control	
of	both	blood	pressure	and	edema	than	reserpine,	an	anti-
hypertensive	drug	no	longer	in	clinical	use	for	many	years	
in	most	countries	[22].	This	result	was	reached	in	the	two	
RCTs	excluded	from	the	meta-analysis	[23,24].	Thus,	the	
limited	relevance	of	these	studies	needs	to	be	emphasized.	
Moreover,	ACE	inhibitors	such	as	captopril	[19]	and	enala-
pril	[20]	had	better	control	of	blood	pressure	and	echocar-
diographic	changes	than	other	antihypertensive	drugs/di-
uretics.	In	agreement,	the	superiority	of	ACE	inhibitors	in	
managing	renal	protection	over	conventional	antihyperten-
sive	regimens	is	suggested	for	several	kidney	diseases	[30].	
Finally,	the	use	of	combined	immunosuppressants	for	cres-
centic	poststreptococcal	glomerulonephritis	showed	no	ad-
vantages,	and	perhaps	more	disadvantages,	than	support-
ive	therapy	alone	[21].
The	available	RCTs	regarding	the	prevention	of	APSGN	and	
treatment	of	its	complications	were	of	poor	quality	concern-
ing	both	evidence	and	thoroughness.	The	applicability	of	the	
clinical	evidence	is	deficient	when	we	consider	the	choice	of	
antimicrobial	treatment	in	preventing	APSGN	following	a	
streptococcal	infection.	Clinicians	are	likely	to	be	reluctant	
to	enroll	children	with	laboratory-proven	streptococcal	in-
fection	into	RCTs	due	to	placebo	harm.	Moreover,	the	avail-
able	RCTs	that	investigated	the	treatment	of	hypertension	
and	related	adverse	heart	conditions	following	APSGN	are	
limited	and	of	poor	quality.	Finally,	one	poor-quality	RCT	
discourages	immunosuppression	for	crescentic	poststrep-
tococcal	biopsy-proven	glomerulonephritis.
The	mortality	from	APSGN	is	said	to	be	approximately	1%.	
Less	than	2%	of	patients	progress	to	end-stage	renal	disease,	
and	most	of	the	sporadic	deaths	and	cases	of	chronic	dis-
ease	occur	in	adults,	whereas	most	epidemic	cases	occur	in	
children,	overall	in	less	developed	countries	[9].	Although	
uncommon,	severe	APSGN	in	Maori	and	Pacific	Island	chil-
dren	resulted	in	a	high	rate	of	long-term	renal	morbidity	
and	the	immunosuppressive	drugs	administered	to	those	pa-
tients	with	crescentic	disease	showed	doubtful	efficacy	[31].
conclusions
Concerning	the	treatment	approach,	we	showed	that	very	
few	and	inconclusive	remarks	are	available	from	the	pub-
lished	controlled	clinical	 trials.	 In	particular,	 the	role	of	
antimicrobials	 in	preventing	the	development	of	APSGN	
remains	unproven.	Poor	data	suggest	the	efficacy	of	ACE	
inhibitors	and	calcium	antagonists	in	managing	hyperten-
sion	in	children	with	APSGN.	Treatment	with	immunosup-
pressive	drugs	during	the	acute	phase	of	disease	may	be	
unnecessary,	of	doubtful	efficacy,	and	sometime	danger-
ous.	Finally,	the	evidence-based	literature	for	the	preven-
tion	and	management	of	APSGN	in	children	is	quite	lim-
ited	and	of	low	overall	quality,	preventing	any	therapeutic	
recommendations.
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